ReviewCVIR endovascular2026
Intra-arterial lidocaine as a pain management strategy for uterine artery embolisation: a systematic review and meta-analysis.
Review in CVIR endovascular, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-procedural pain remains a significant challenge following uterine artery embolisation (UAE) and intra-arterial lidocaine (IAL) has emerged as a potential adjunctive analgesic. This systematic review and meta-analysis evaluated the efficacy and safety of IAL during UAE. MEDLINE, Embase, and the Cochrane Library were searched from inception to June 2026, identifying eight studies including 692 patients. IAL significantly reduced pain at 4 h post-procedure and lowered the maximum pain experienced within the first 24 h. However, there were no significant differences in pain immediately after the procedure, at 7 or 24 h, opioid consumption, or inflammatory markers. Serious adverse events were uncommon. These findings suggest that IAL provides meaningful early pain relief and may serve as a safe adjunct in pain management for UAE. Systematic review registration PROSPERO CRD420261428710.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.